Which has higher earnings & valuation, DWTX or KTTA?

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A

Is DWTX or KTTA more profitable?

Pasithea Therapeutics' return on equity of -57.44% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -108.57% -30.28% Pasithea Therapeutics N/A -57.44% -53.61%

Do analysts prefer SCLX or KTTA?

Pasithea Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 439.67%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Pasithea Therapeutics is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer LTRN or KTTA?

Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 439.67%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, LTRN or KTTA?

Lantern Pharma is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.45 N/A Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A

Is LTRN or KTTA more profitable?

Pasithea Therapeutics' return on equity of -57.44% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -198.34% -129.08% Pasithea Therapeutics N/A -57.44% -53.61%

Is KTTA or HYPD more profitable?

Pasithea Therapeutics' return on equity of -57.44% beat Hyperion DeFi's return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -57.44% -53.61% Hyperion DeFi N/A -91.59% -73.08%

Which has higher earnings & valuation, ACTU or KTTA?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A

Is ACTU or KTTA more profitable?

Pasithea Therapeutics' return on equity of -57.44% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% Pasithea Therapeutics N/A -57.44% -53.61%

Pasithea Therapeutics (KTTA) Competitors

$0.56 -0.01 (-2.13%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$0.56 +0.00 (+0.02%)

As of 06/24/2026 04:10 PM Eastern

Compare

KTTA vs. DWTX, SCLX, LTRN, HYPD, and ACTU

Should you buy Pasithea Therapeutics stock or one of its competitors? MarketBeat compares Pasithea Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pasithea Therapeutics include Dogwood Therapeutics (DWTX), Scilex (SCLX), Lantern Pharma (LTRN), Hyperion DeFi (HYPD), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry.

How does Pasithea Therapeutics compare to Dogwood Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Pasithea Therapeutics' return on equity of -57.44% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
Pasithea Therapeutics	N/A	-57.44%	-53.61%

Dogwood Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 694.70%. Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 439.67%. Given Dogwood Therapeutics' higher possible upside, equities research analysts clearly believe Dogwood Therapeutics is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dogwood Therapeutics has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

In the previous week, Dogwood Therapeutics' average media sentiment score of 0.00 equaled Pasithea Therapeutics'average media sentiment score.

Company	Overall Sentiment
Dogwood Therapeutics	Neutral
Pasithea Therapeutics	Neutral

Summary

Pasithea Therapeutics beats Dogwood Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Scilex?

Scilex (NASDAQ:SCLX) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

In the previous week, Scilex had 2 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Scilex and 0 mentions for Pasithea Therapeutics. Scilex's average media sentiment score of 0.67 beat Pasithea Therapeutics' score of 0.00 indicating that Scilex is being referred to more favorably in the media.

Company	Overall Sentiment
Scilex	Positive
Pasithea Therapeutics	Neutral

Pasithea Therapeutics has lower revenue, but higher earnings than Scilex. Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	1.93	-$358.73M	-$40.47	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

Pasithea Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,110.17%	N/A	-143.55%
Pasithea Therapeutics	N/A	-57.44%	-53.61%

69.7% of Scilex shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 4.5% of Scilex shares are owned by insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Scilex has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

Pasithea Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 439.67%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Pasithea Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Scilex beats Pasithea Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 439.67%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Lantern Pharma's average media sentiment score of 0.00 equaled Pasithea Therapeutics'average media sentiment score.

Company	Overall Sentiment
Lantern Pharma	Neutral
Pasithea Therapeutics	Neutral

Lantern Pharma is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

Pasithea Therapeutics' return on equity of -57.44% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-198.34%	-129.08%
Pasithea Therapeutics	N/A	-57.44%	-53.61%

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by company insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Lantern Pharma has a beta of 2.33, indicating that its share price is 133% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Summary

Pasithea Therapeutics beats Lantern Pharma on 6 of the 11 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Hyperion DeFi?

Pasithea Therapeutics (NASDAQ:KTTA) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 7.5% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pasithea Therapeutics has higher earnings, but lower revenue than Hyperion DeFi. Hyperion DeFi is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Hyperion DeFi	$810K	63.63	-$45.31M	-$9.95	N/A

In the previous week, Hyperion DeFi had 3 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 3 mentions for Hyperion DeFi and 0 mentions for Pasithea Therapeutics. Hyperion DeFi's average media sentiment score of 0.44 beat Pasithea Therapeutics' score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the news media.

Company	Overall Sentiment
Pasithea Therapeutics	Neutral
Hyperion DeFi	Neutral

Pasithea Therapeutics' return on equity of -57.44% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Hyperion DeFi	N/A	-91.59%	-73.08%

Pasithea Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 439.67%. Hyperion DeFi has a consensus price target of $5.65, suggesting a potential upside of 66.18%. Given Pasithea Therapeutics' higher possible upside, equities analysts plainly believe Pasithea Therapeutics is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Pasithea Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Hyperion DeFi has a beta of 2.47, meaning that its share price is 147% more volatile than the broader market.

Summary

Hyperion DeFi beats Pasithea Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

In the previous week, Actuate Therapeutics' average media sentiment score of 0.00 equaled Pasithea Therapeutics'average media sentiment score.

Company	Overall Sentiment
Actuate Therapeutics	Neutral
Pasithea Therapeutics	Neutral

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

Actuate Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Pasithea Therapeutics' return on equity of -57.44% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Pasithea Therapeutics	N/A	-57.44%	-53.61%

Actuate Therapeutics currently has a consensus price target of $17.50, indicating a potential upside of 797.44%. Pasithea Therapeutics has a consensus price target of $3.00, indicating a potential upside of 439.67%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

23.9% of Pasithea Therapeutics shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Actuate Therapeutics beats Pasithea Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KTTA vs. The Competition

Export

Metric	Pasithea Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.17M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-0.27	20.50	25.39	23.96
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	0.23	8.26	10.76	6.41
Net Income	-$20.43M	$23.91M	$3.56B	$337.14M
7 Day Performance	10.67%	3.05%	1.37%	-0.48%
1 Month Performance	-20.56%	2.40%	0.81%	0.49%
1 Year Performance	-23.95%	56.35%	30.53%	28.16%

Pasithea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KTTA Pasithea Therapeutics	2.9455 of 5 stars	$0.56 -2.1%	$3.00 +439.7%	-24.0%	$14.17M	N/A	N/A	3	Gap Up
DWTX Dogwood Therapeutics	3.3155 of 5 stars	$1.49 -0.7%	$12.00 +705.4%	-68.9%	$50.44M	N/A	N/A	5	Gap Up
SCLX Scilex	0.6396 of 5 stars	$6.94 +18.0%	N/A	+24.7%	$49.93M	$30.25M	N/A	80	Gap Down
LTRN Lantern Pharma	0.7311 of 5 stars	$3.89 -0.5%	N/A	+23.1%	$49.89M	N/A	N/A	20	Positive News
HYPD Hyperion DeFi	4.0594 of 5 stars	$3.53 +9.0%	$5.65 +60.1%	-62.3%	$49.11M	$810K	N/A	40	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KTTA) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. DWTX, SCLX, LTRN, HYPD, and ACTU

How does Pasithea Therapeutics compare to Dogwood Therapeutics?

Summary

How does Pasithea Therapeutics compare to Scilex?

Summary

How does Pasithea Therapeutics compare to Lantern Pharma?

Summary

How does Pasithea Therapeutics compare to Hyperion DeFi?

Summary

How does Pasithea Therapeutics compare to Actuate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. DWTX, SCLX, LTRN, HYPD, and ACTU

How does Pasithea Therapeutics compare to Dogwood Therapeutics?

Which has higher earnings & valuation, DWTX or KTTA?

Do institutionals & insiders have more ownership in DWTX or KTTA?

Is DWTX or KTTA more profitable?

Do analysts prefer DWTX or KTTA?

Which has more risk and volatility, DWTX or KTTA?

Does the media prefer DWTX or KTTA?

Summary

How does Pasithea Therapeutics compare to Scilex?

Does the media prefer SCLX or KTTA?

Which has preferable valuation & earnings, SCLX or KTTA?

Is SCLX or KTTA more profitable?

Do institutionals and insiders hold more shares of SCLX or KTTA?

Which has more volatility and risk, SCLX or KTTA?

Do analysts prefer SCLX or KTTA?

Summary

How does Pasithea Therapeutics compare to Lantern Pharma?

Do analysts prefer LTRN or KTTA?

Does the media favor LTRN or KTTA?

Which has stronger earnings and valuation, LTRN or KTTA?

Is LTRN or KTTA more profitable?

Do insiders and institutionals hold more shares of LTRN or KTTA?

Which has more volatility & risk, LTRN or KTTA?

Summary

How does Pasithea Therapeutics compare to Hyperion DeFi?

Do insiders & institutionals hold more shares of KTTA or HYPD?

Which has higher valuation & earnings, KTTA or HYPD?

Does the media refer more to KTTA or HYPD?

Is KTTA or HYPD more profitable?

Do analysts recommend KTTA or HYPD?

Which has more risk & volatility, KTTA or HYPD?

Summary

How does Pasithea Therapeutics compare to Actuate Therapeutics?

Does the media prefer ACTU or KTTA?

Which has higher earnings & valuation, ACTU or KTTA?

Which has more risk and volatility, ACTU or KTTA?

Is ACTU or KTTA more profitable?

Do analysts recommend ACTU or KTTA?

Do institutionals & insiders believe in ACTU or KTTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools